Brokerages Set Haemonetics Corporation (NYSE:HAE) PT at $82.78

Shares of Haemonetics Corporation (NYSE:HAE) have received an average recommendation of “Moderate Buy” from the eleven ratings firms that are covering the company, Marketbeat.com reports. Four analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $79.8889.

A number of research firms recently weighed in on HAE. Barrington Research set a $94.00 price target on shares of Haemonetics in a research report on Friday, February 6th. Citigroup lowered their price target on shares of Haemonetics from $75.00 to $70.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 11th. JPMorgan Chase & Co. dropped their price target on Haemonetics from $74.00 to $62.00 and set a “neutral” rating for the company in a research report on Friday. BTIG Research restated a “buy” rating and issued a $88.00 price target on shares of Haemonetics in a research report on Friday, February 6th. Finally, Mizuho lowered their price objective on Haemonetics from $80.00 to $70.00 and set an “outperform” rating on the stock in a research note on Monday, April 13th.

Haemonetics Price Performance

Shares of NYSE HAE opened at $55.06 on Tuesday. The firm has a market cap of $2.56 billion, a PE ratio of 27.26, a PEG ratio of 1.08 and a beta of 0.53. The firm has a fifty day moving average of $59.53 and a 200 day moving average of $66.68. The company has a debt-to-equity ratio of 1.53, a quick ratio of 1.15 and a current ratio of 2.95. Haemonetics has a one year low of $47.31 and a one year high of $87.32.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.01. Haemonetics had a net margin of 7.29% and a return on equity of 27.30%. The business had revenue of $346.35 million during the quarter, compared to analyst estimates of $336.83 million. During the same quarter in the prior year, the firm earned $1.24 earnings per share. The company’s revenue for the quarter was up 4.8% compared to the same quarter last year. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. As a group, research analysts predict that Haemonetics will post 5.28 EPS for the current fiscal year.

Institutional Investors Weigh In On Haemonetics

A number of hedge funds have recently modified their holdings of the company. Dimensional Fund Advisors LP grew its holdings in shares of Haemonetics by 21.3% in the first quarter. Dimensional Fund Advisors LP now owns 1,326,057 shares of the medical instruments supplier’s stock valued at $74,731,000 after purchasing an additional 233,119 shares during the period. Heartland Advisors Inc. grew its holdings in shares of Haemonetics by 13.3% in the first quarter. Heartland Advisors Inc. now owns 85,000 shares of the medical instruments supplier’s stock valued at $4,791,000 after purchasing an additional 10,000 shares during the period. Jennison Associates LLC increased its holdings in shares of Haemonetics by 86.2% during the 1st quarter. Jennison Associates LLC now owns 22,536 shares of the medical instruments supplier’s stock worth $1,270,000 after buying an additional 10,433 shares during the last quarter. Aurora Investment Counsel acquired a new stake in shares of Haemonetics during the 1st quarter worth approximately $1,217,000. Finally, Principal Financial Group Inc. lifted its holdings in Haemonetics by 25.4% in the first quarter. Principal Financial Group Inc. now owns 205,456 shares of the medical instruments supplier’s stock valued at $11,580,000 after acquiring an additional 41,677 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Key Stories Impacting Haemonetics

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Haemonetics reported fiscal Q4 results that topped expectations, with EPS of $1.29 vs. $1.28 expected and revenue of $346.35 million vs. $336.83 million expected, while revenue rose 4.8% year over year. Haemonetics (NYSE:HAE) Reports Upbeat Q1 CY2026
• Positive Sentiment: The company also guided FY 2027 EPS to $5.258-$5.307 and reiterated revenue around $1.4 billion, signaling continued growth from Persona PLUS rollout and a rebound in IVT volumes. Haemonetics projects FY 2027 revenue growth of 4% to 7% as Persona PLUS rollout and IVT rebound efforts continue
• Neutral Sentiment: JPMorgan lowered its price target on Haemonetics to $62 from $74 and kept a Neutral rating, reflecting more cautious expectations even though the new target still sits above the recent share price. Read More
• Neutral Sentiment: Several earnings call transcripts and summaries were published, but they mainly reinforce the same themes of modest earnings beats and management’s forward guidance. Haemonetics (HAE) Q4 2026 Earnings Transcript

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.